These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 18586694)

  • 21. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.
    Lewis DA; Moghaddam B
    Arch Neurol; 2006 Oct; 63(10):1372-6. PubMed ID: 17030651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oscillatory, Computational, and Behavioral Evidence for Impaired GABAergic Inhibition in Schizophrenia.
    Shaw AD; Knight L; Freeman TCA; Williams GM; Moran RJ; Friston KJ; Walters JTR; Singh KD
    Schizophr Bull; 2020 Feb; 46(2):345-353. PubMed ID: 31219602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synapse-specific contributions in the cortical pathology of schizophrenia.
    Seshadri S; Zeledon M; Sawa A
    Neurobiol Dis; 2013 May; 53():26-35. PubMed ID: 23336981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in cortical interneurons and cognitive function in schizophrenia.
    Dienel SJ; Lewis DA
    Neurobiol Dis; 2019 Nov; 131():104208. PubMed ID: 29936230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A computational neuroscience approach to schizophrenia and its onset.
    Rolls ET; Deco G
    Neurosci Biobehav Rev; 2011 Aug; 35(8):1644-53. PubMed ID: 20851143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synaptic activation of GABA(B) receptors regulates neuronal network activity and entrainment.
    Brown JT; Davies CH; Randall AD
    Eur J Neurosci; 2007 May; 25(10):2982-90. PubMed ID: 17561812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fiber pathway pathology, synapse loss and decline of cortical function in schizophrenia.
    Bennett MR; Farnell L; Gibson WG
    PLoS One; 2013; 8(4):e60518. PubMed ID: 23593232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.
    Hashimoto T; Bazmi HH; Mirnics K; Wu Q; Sampson AR; Lewis DA
    Am J Psychiatry; 2008 Apr; 165(4):479-89. PubMed ID: 18281411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction.
    Lewis DA; Volk DW; Hashimoto T
    Psychopharmacology (Berl); 2004 Jun; 174(1):143-50. PubMed ID: 15205885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia.
    Volk DW; Austin MC; Pierri JN; Sampson AR; Lewis DA
    Arch Gen Psychiatry; 2000 Mar; 57(3):237-45. PubMed ID: 10711910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions.
    Deutsch SI; Rosse RB; Schwartz BL; Mastropaolo J; Burket JA; Weizman A
    Isr J Psychiatry Relat Sci; 2010; 47(1):17-26. PubMed ID: 20686196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting synapses and myelin in the prevention of schizophrenia.
    Woo TU; Crowell AL
    Schizophr Res; 2005 Mar; 73(2-3):193-207. PubMed ID: 15653262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered Markers of Cortical γ-Aminobutyric Acid Neuronal Activity in Schizophrenia: Role of the NARP Gene.
    Kimoto S; Zaki MM; Bazmi HH; Lewis DA
    JAMA Psychiatry; 2015 Aug; 72(8):747-56. PubMed ID: 26038830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited.
    Winterer G
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S68-71. PubMed ID: 16508900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.
    Xu MY; Wong AHC
    Acta Pharmacol Sin; 2018 May; 39(5):733-753. PubMed ID: 29565038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies.
    Stan AD; Lewis DA
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1557-62. PubMed ID: 22283765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neural synchrony in schizophrenia: from networks to new treatments.
    Ford JM; Krystal JH; Mathalon DH
    Schizophr Bull; 2007 Jul; 33(4):848-52. PubMed ID: 17567628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seizures beget seizures: the quest for GABA as a key player.
    Ben-Ari Y
    Crit Rev Neurobiol; 2006; 18(1-2):135-44. PubMed ID: 17725516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients.
    Frankle WG; Cho RY; Prasad KM; Mason NS; Paris J; Himes ML; Walker C; Lewis DA; Narendran R
    Am J Psychiatry; 2015 Nov; 172(11):1148-59. PubMed ID: 26133962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression.
    Yoon JH; Maddock RJ; Rokem A; Silver MA; Minzenberg MJ; Ragland JD; Carter CS
    J Neurosci; 2010 Mar; 30(10):3777-81. PubMed ID: 20220012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.